Humegon market to grow on infertility demand and fertility tourism

The Business Research Company says the Humegon market is being lifted by rising infertility rates, delayed parenthood, more IVF use and growing fertility clinics. North America led the market in 2025, while Asia-Pacific is expected to grow fastest over the forecast period.

Why it matters: - Humegon sits inside a broader fertility market that is expanding as more people seek assisted reproductive treatments. - Rising infertility, older parenthood and wider IVF use are increasing demand for menotropin-based therapies. - The market's regional shift matters because North America already leads, while Asia-Pacific is expected to post the fastest growth.

What happened: - The Business Research Company published an analysis of the competitive landscape of the global Humegon market. - The report says Humegon market growth has been driven by rising infertility rates, delayed parenthood, proven effectiveness of menotropin-based therapies, more fertility clinics and broader acceptance of IVF. - The report says future growth will be supported by better access to fertility care, reproductive medicine technology, more male infertility diagnoses, supportive reimbursement and fertility tourism. - North America was the largest Humegon market in 2025. - Asia-Pacific is expected to be the fastest-growing region over the forecast period. - The report covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The report also includes market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies, future trend analysis and updated graphics and tables.

The details: - Humegon contains menotropins, a combination of follicle-stimulating hormone and luteinizing hormone extracted from the urine of postmenopausal women. - Humegon is used in assisted reproductive technologies such as IVF to stimulate ovarian function and encourage the production of multiple follicles and eggs. - Humegon may also be prescribed for men with low sperm production. - The report defines infertility as the inability to conceive after one year of regular, unprotected intercourse. - The report links infertility growth to postponed childbearing, unhealthy lifestyle choices, obesity, environmental pollutants and broader diagnosis rates. - Data from the UK Office for Health Improvement & Disparities showed that 64.0% of adults aged 18 and above in England were overweight or obese in 2022-2023. - The report says obesity is closely linked with infertility, which supports demand for treatments like Humegon. - Population Reference Bureau data from January 2024 projects the US population aged 65 and older will rise from 58 million in 2022 to 82 million by 2050. - That would increase the share of the total US population age 65 and older from 17% to 23%. - The report says precision medicine is also supporting market growth by pushing more personalized fertility treatment protocols. - Personalized Medicine Coalition data from February 2024 says the FDA approved 16 new personalized treatments for rare diseases in 2023, up from six in 2022. - Among those approvals, seven were cancer drugs and three targeted other conditions.

Between the lines: - The market story is not just about fertility drugs. It is also about how demographics, reimbursement and personalized care are reshaping treatment demand. - Male infertility is becoming a more visible growth driver, which could broaden the use cases for Humegon and similar therapies. - The Asia-Pacific growth outlook suggests fertility treatment demand may be accelerating beyond traditional US and European hubs.

What's next: - The report points to continued gains from assisted reproductive technologies, tailored stimulation protocols and expanded treatments for male infertility. - Increased access to fertility care and fertility tourism could widen the market base in the forecast period. - The company is offering a free sample report and a full market report through its website.